ZAYO-GROUP
16.1.2023 14:01:42 CET | Business Wire | Press release
Zayo Group Holdings, Inc., a leading global communications infrastructure platform, announced the deployment of a new 400G enabled route connecting Paris and Marseille—including first-in-market network hardening of this critical route leveraging next-generation fiber technologies—to provide enterprises with an easier and more secure way to transport rapidly increasing high-bandwidth traffic from these top-ten global internet hubs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005067/en/
Map of Zayo's new 400G enabled route connecting Paris and Marseille (Graphic: Business Wire)
“We are continuously expanding, improving and diversifying our network in order to support our customers with their increasing bandwidth,” said Yannick Leboyer, Europe Chief Operating Officer at Zayo. “With several new subsea cable projects set to deploy in the coming years, Marseille is on its way to becoming one of the top five internet connectivity hubs globally, and Zayo is uniquely positioned to provide the necessary infrastructure to support this growth. The Paris-to-Marseille route is built to support and transport the fast-paced bandwidth growth and increasingly high demand for connectivity in these markets, giving customers a more reliable, scalable and secure way to share data to the rest of Europe and the U.S.”
Paris is the fourth largest internet connectivity hub in the world, and Marseille, a crossroad of several major exchanges between terrestrial and submarine networks, is projected to move from the seventh to the fifth largest global internet hub in the next three years. With six new subsea cables in Marseille scheduled for completion, including key gateways to Asia, Africa and the Middle East, capacity demands in Marseille are expected to quadruple by 2026. This is creating a rapidly increasing need for enterprises to transport traffic growth from these hubs throughout Europe and to other key commerce centers across the globe.
The new Paris-to-Marseille route from Zayo provides 24 terabytes of total expected capacity per fiber pair, critical triversity options, and 400G enablement for enterprises to manage this capacity growth and ensure secure, resilient connectivity to the rest of Europe and the United States. Beyond capacity, Zayo is hardening its network with new fiber technologies, making Zayo the first carrier with this next-generation fiber on the route connecting Paris to Marseille.
The route will also provide direct access to Bordeaux—the landing city for Amitié, a new private transatlantic cable that will connect the U.S. with the UK and France. Once ready for service, the connection will enable direct access to Asia, Africa, and the Middle East.
This latest investment from Zayo is part of the company’s overall strategy to overlay its European backbone and deliver high-capacity bandwidth across Europe, following the completion of its Zeus subsea cable in 2022, which provides the strongest connection between the UK and continental Europe. To date, Zayo owns and operates 2.2 million kilometers of fiber and connects 16 key metro markets and nine countries across Europe.
To learn more about Zayo’s global network, please visit https://www.zayo.com/network/.
About Zayo Group Holdings, Inc.
Zayo Group Holdings, Inc. is the leading global communications infrastructure platform, delivering a range of solutions, including fiber & transport, packet and managed edge services. Zayo owns and operates a Tier 1 IP backbone spanning 137,000 miles across North America and Europe. By providing this mission-critical bandwidth to its category-leading customers across the wireless, hyperscale, media, tech and finance industries, Zayo is fueling the innovations that are transforming society. For more information, visit https://zayo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
